Unlike in the West, Japanese startups often rush to an IPO not as a culmination of growth, but as a substitute for late-stage venture funding. This premature listing distracts from long-term global expansion, resulting in a market of small, stagnant companies.
A study of 23,000 Americans revealed a direct correlation between procrastination and income. For each one-point increase on a five-point self-assessed procrastination scale, individuals experienced a $15,000 drop in annual earnings, highlighting a significant, measurable financial impact.
Overcoming the physical discomfort of exercise creates a psychological "sense of mastery." This boosts confidence and self-regulatory skills, which then transfers to other areas, making individuals more likely to tackle unpleasant or difficult tasks instead of delaying them.
The breakthrough behind orexin agonist drugs, a potential successor to GLP-1s, came from studying narcolepsy in dogs. A Stanford researcher identified a genetic mutation in Dobermans and Labradors that prevented them from responding to the orexin molecule, directly linking it to wakefulness and creating a path for new human therapies.
While Japan is producing more unicorns, it lacks a "Decacorn" ($10B+ startup). A company of this scale is crucial not just for its own success, but to act as a motivated, large-scale acquirer of promising young companies, providing vital exit opportunities and stimulating the entire ecosystem, much like Google does in Silicon Valley.